CHIOME BIOSCIENCE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 127 JPY | -2.31% |
|
-4.51% | -5.93% |
| Apr. 01 | Chiome Bioscience Cancels License Agreements with ADC Therapeutics | MT |
| Feb. 13 | Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited | CI |
More news
More press releases
| 1 day | -2.31% | ||
| 1 week | -4.51% | ||
| Current month | -11.19% | ||
| 1 month | -9.29% | ||
| 3 months | -8.63% | ||
| 6 months | +0.79% | ||
| Current year | -5.93% |
1 week
126.00
133.00
1 month
126.00150.00
Current year
126.00174.00
1 year
117.00234.00
3 years
117.00386.00
5 years
117.00484.00
10 years
117.002 548.00
| Managers | Title | Age | Since |
|---|---|---|---|
| President | 70 | 09-03-31 | |
Arihiko Bijohira
BRD | Director/Board Member | 45 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Akiyuki Furuya
BRD | Director/Board Member | 79 | 17-02-28 |
Haruhisa Kubota
BRD | Director/Board Member | 74 | 19-03-27 |
| President | 70 | 09-03-31 |
Chiome Bioscience Inc. is a company mainly engaged in the research and development of antibody drugs, and the provision of development support services. The Company operates in two business segments. The Drug Discovery segment is engaged in the research and development of specific antibodies based on new antigens and mechanisms and licensing to pharmaceutical companies. The Drug Discovery Support segment is engaged in development of lead antibodies for therapeutic drugs in collaborating with pharmaceutical companies in Japan and overseas.
Calendar
2024-05-13
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -5.93% | 46.21M | |
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| +1.97% | 39.05B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B |
- Stock Market
- Equities
- 4583 Stock
